What is Omeza?
Omeza is at the forefront of regenerative skincare, developing advanced medical solutions designed to restore skin integrity and enhance healing outcomes for patients with complex dermatological conditions. The company's product portfolio addresses critical unmet clinical needs in wound care by supporting multiple stages of the healing process, including inflammation control, tissue regeneration, and skin repair. Omeza's healthcare provider-administered products are engineered to optimize healing without reliance on software or digital services, positioning it as a key player in the medical device and biotechnology sectors.
How much funding has Omeza raised?
Omeza has raised a total of $15.8M across 4 funding rounds:
Seed
$7M
Debt
$150K
Debt
$180K
Series A
$8.5M
Seed (2019): $7M, investors not publicly disclosed
Debt (2020): $150K led by PPP
Debt (2021): $180K supported by PPP
Series A (2026): $8.5M featuring Astanor Ventures, Catalyst Fund, BluKap, and Florida Opportunity Fund
Key Investors in Omeza
Astanor Ventures
Astanor Ventures is a venture capital firm dedicated to transforming the agrifood system through innovation and impact, investing in solutions that promote sustainability, health, and equity across the global food value chain.
Catalyst Fund
Catalyst Investments is an Israeli multi-fund firm specializing in investment and value creation for technology companies, focusing on disruptive technologies with an Israeli nexus and prioritizing social responsibility.
BluKap
BluKap is a venture capital firm focused on driving innovation in the ocean economy, investing in late seed and Series A companies to foster sustainable business solutions and international growth.
What's next for Omeza?
With the infusion of $8.5M in a major strategic investment, Omeza is poised for significant expansion. This capital injection, part of its $15.8M in total financing, will likely fuel further research and development, clinical trials, and market penetration for its regenerative therapies. The company's focus on addressing chronic wound care challenges aligns with growing healthcare demands, suggesting a strategic push to scale operations and broaden its therapeutic reach. Future growth may involve strategic partnerships and expanded product lines to solidify its position in the competitive regenerative medicine landscape.
See full Omeza company page
